OncoMatch/Clinical Trials/NCT02443831
CARPALL: Immunotherapy with CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
Is NCT02443831 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including CD19+CD22 CAR T-cells and Lymphodepletion with Fludarabine for acute lymphoblastic leukemia.
Treatment: Lymphodepletion with Fludarabine · Lymphodepletion with Cyclophosphamide · CD19+CD22 CAR T-cells — This study aims to evaluate the safety, efficacy and duration of response of CD19+CD22 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in children with high risk, relapsed CD19+ and CD22+ acute lymphoblastic leukaemia
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 overexpression (positive)
CD19+ acute lymphoblastic leukaemia
Required: CD22 overexpression (positive)
CD22+ acute lymphoblastic leukaemia
Allowed: KMT2A (MLL) rearrangement
MLL gene rearrangement
Allowed: TCF3 HLF rearrangement
t(17,19) TCF3-HLF rearrangement
Allowed: TCF3 PBX1 rearrangement
t(1;19)(q21;p13)/TCF3-PBX1
Allowed: BCR ABL1 rearrangement
t(9;22)(34.1 q11.2)/BCR-ABL1
Lab requirements
Kidney function
creatinine > 3 x upper limit of normal
Liver function
bilirubin > 3 x upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify